Labetalol for hypertension during pregnancy and nipple pain

Rolfes, Leàn; Swart-Ruijter, Irene de; Hunsel, Florence van

doi:10.1016/j.ejogrb.2014.09.041

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three cases of pregnant women who experienced nipple pain after use of labetalol were reported to the Netherlands Pharmacovigilance Centre, which maintains that country's voluntary adverse drug reaction reporting system [10]. Interestingly, in the three cases reported, the onset of nipple discomfort coincided with the maximum plasma concentration of labetalol, which is reached within 30–60 min [11]. In addition to these cases, there has been one official case report, from the United Kingdom, of nipple pain experienced by a pregnant female after labetalol use [7].…”

Section: Discussionmentioning

confidence: 99%

Raynaud's phenomenon of the nipple as a side-effect of labetalol: Case report and literature review

Avila-Vega

Urrea-Mendoza

Lee

2019

Case Reports in Women's Health

View full text Add to dashboard Cite

Raynaud's phenomenon of the nipple is an unusual side-effect of labetalol use. There is one official report from the United Kingdom. The present case concerns a 30-year-old woman, gravida 1, para 0, who developed pre-eclampsia and was treated with labetalol but subsequently reported neuropathic pain of the nipple. Nifedipine was then started as part of her treatment plan for blood pressure control and she no longer reported pain, despite being given six more doses of labetalol. Nifedipine is the first-line of treatment for Raynaud's phenomenon. The concomitant use of labetalol with nifedipine by a woman with Raynaud's phenomenon of the nipple has not been discussed before. The goal of this review is to raise awareness of this drug-induced phenomenon and to add to the limited literature available on this subject.

show abstract

Section: Discussionmentioning

confidence: 99%

Raynaud's phenomenon of the nipple as a side-effect of labetalol: Case report and literature review

Avila-Vega

Urrea-Mendoza

Lee

2019

Case Reports in Women's Health

View full text Add to dashboard Cite

show abstract

“…Три подобных случая были зарегистри-Adverse events of beta-blockers Нежелательные явления бета-адреноблокаторов рованы в Нидерландском центре фармаконадзора на основании данных, полученных в виде добровольной отчетности о НР на лекарственные средства. Важно отметить, что во всех представленных случаях возникновение похолодания сосков совпало по времени с максимальной концентрацией лабеталола в плазме крови беременных женщин [35]. Единичные случаи развития синдрома Рейно сосков при применении лабеталола были официально зарегистрированы в Соединенном Королевстве и США [36,37].…”

Section: синдром рейноunclassified

Peculiarities of Adverse Events Manifested by Injury of Skin and Skin Derivatives and Associated with Beta-blockers Use

Matveev

Egorova

Konyaeva

et al. 2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

More than 50 years after Propranolol was introduced to the pharmaceutical market as a drug that can lower the heart rate, beta-blockers (BAB) are still widely used in the pharmacotherapy of cardiovascular diseases. However, the use of BAB has a number of limitations, first of all, due to adverse drug events (AE) that develop during their use. The purpose of our review was to study the features of the BAB AE manifested by injuries of the skin and its appendages. The clinical manifestations of them are the development or exacerbation of psoriasis, lichen planus, contact dermatitis, acrocyanosis, Raynaud's disease, alopecia, hyperhidrosis, vitiligo, anaphylaxis, and allergic skin reactions. True medicinal psoriasis occurs in patients taking BAB with no family or previous history and most often mimics erythrodermic psoriasis and palmar-plantar pustular psoriasis. Systemic use of BAB can also be accompanied by exacerbation of vitiligo. In patients with segmental vitiligo, the results of Doppler flowmetry and iontophoresis showed increased blood flow in vitiligo foci compared with normal skin. The development of anaphylactic reactions against the background of BAB therapy may be due to the modulation of adenylate cyclase, which can affect the release of anaphylactogenic mediators, as well as a decrease in the severity of cardiovascular compensatory changes. The peculiarities of the development of such reactions may be the resistance of patients to traditional treatment, which is due to the development of paradoxical reflex vagotonic effects when using adrenaline. Some of the mentioned AE may pose a potential threat to the life and health of the patient and therefore require additional discussion.

show abstract

“…[12] In addition, there is a causal association between labetalol and nipple pain in pregnant women. [13] The management of preeclampsia is a balance between risk and associated therapy-related toxic effects in cardiovascular diseases. [12] Oral nifedipine is generally used by obstetricians in pregnant women for the management of hypertension in preeclampsia but it has slower management of hypertension and the effects are not last long.…”

Section: Introductionmentioning

confidence: 99%

Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia

Peng,

Zhang,

Xiao

et al. 2023

Medicine

View full text Add to dashboard Cite

As per the American College of Obstetricians and Gynecologists in 2013, magnesium sulfate is the gold standard for the management of preeclampsia, but it has a short action time that does not provide stable maintenance of blood pressure. Labetalol is currently recommended as first-line treatment by the national UK guidance. This study included 355 pregnant Han Chinese women with preeclampsia and aimed to compare outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine. Women received 4 g intravenous magnesium sulfate followed by the maintenance dose of 1 g/h intravenous magnesium sulfate (MS cohort, n = 104) or intravenous labetalol (LB cohort, n = 115), or oral nifedipine (NF cohort, n = 136). Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL). Women of all cohorts successfully decreased systolic and diastolic blood pressures at EL as compared to them before therapy conditions (P < .001, for all). At EL, systolic and diastolic blood pressures of women of the LB cohort decreased more than those of women of the MS and NF cohorts (P < .05, for all). Therapy was more successful in women of the LB cohort than those of the NF cohort (107 [93%] vs 112 [82%], P = .0132). More numbers of women were reduced blood pressure after 1 day of therapy from the LB cohort than those of the NF (75 [65%] vs 21 [15%]) and MS (75 [65%] vs 35 [34%]) cohorts (P < .0001 for both). Labetalol-induced tachycardia, bradycardia, and intracranial hemorrhage in pregnant women and respiratory distress syndrome and hypoglycemia in neonates. Intravenous labetalol provides proper reduction of blood pressure in Han Chinese women with preeclampsia but has the risk of undesirable maternal and neonatal adverse effects (Level of Evidence: IV; Technical Efficacy: Stage 4).

show abstract

Labetalol for hypertension during pregnancy and nipple pain

Cited by 4 publications

References 5 publications

Raynaud's phenomenon of the nipple as a side-effect of labetalol: Case report and literature review

Raynaud's phenomenon of the nipple as a side-effect of labetalol: Case report and literature review

Peculiarities of Adverse Events Manifested by Injury of Skin and Skin Derivatives and Associated with Beta-blockers Use

Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia

Contact Info

Product

Resources

About